Intuitive Surgical, Inc. ISRG
Healthcare · Medical Instruments & Supplies · United States · S&P 500
Based on the available data, Intuitive Surgical, Inc. gets an algorithmic score of 61/100. It trades at 412.18 $, with a bearish technical trend (RSI 67.2) and 36.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High net margin (28.4%): pricing power / competitive advantage.
- Sustained revenue growth (17.4% compound annual).
Weaknesses
- —
Fundamentals
| P/E | 47.60 |
| Forward P/E | 34.09 |
| PEG | 1.87 |
| P/B | 8.03 |
| EV/EBITDA | 33.61 |
| P/S | 13.38 |
| ROE % | 17.42 |
| ROA % | 10.51 |
| Gross margin % | 66.68 |
| Operating margin % | 33.60 |
| Net margin % | 28.45 |
| Revenue growth % (y/y) | 18.50 |
| Earnings growth % (y/y) | 26.50 |
| Revenue CAGR % | 17.39 |
| Earnings CAGR % | 29.26 |
| Current ratio | 4.96 |
| FCF yield % | 1.69 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +10.6 % |
| 3 months | +3.6 % |
| 6 months | -9.0 % |
| YTD | -26.7 % |
| 1 year | -6.6 % |
| 3 years | +43.0 % |
| 5 years | +21.9 % |
Risk
| 1-year volatility | 36.8 % |
| Beta | 0.77 |
| 5-year max drawdown | -49.9 % |
| Sharpe 1A | -0.11 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.